Citations

Clear

4610 citation(s) found for "Lu, Brian".

Race-free estimated glomerular filtration rate equation in kidney transplant recipients: development and validation study
Raynaud, Marc , Awadhi, Solaf Al, Divard, Gillian , Dubourg, Laurence , Mariat, Christophe , Prié, Dominique , Pernin, Vincent , Larson, Timothy S., Bikbov, Boris , Ruggenenti, Piero , Ibrahim, Hassan N. , Nielsen, Marie Bodilsen , Matas, Arthur J. , Nankivell, Brian J. , Benjamens, Stan , Pol, Robert A. , Bakker, Stephan J. L. , Jouven, Xavier , Legendre, Christophe , Wadei, Hani M. , Dürrbach, Antoine , Vincenti, Flavio , Lefaucheur, Carmen , Loupy, Alexandre , Wadei, Hani M , Al-Awadhi, Solaf , Divard, Gillian , Jurić, Ivana , Lombardi, Yannis , Bašić‐Jukić, Nikolina , Aubert, Olivier , Masson, Ingrid , Quintrec, Moglie Le , Stegall, Mark D. , Mesnard, Laurent , Kamar, Nassim , Smith, Byron H. , Remuzzi, Giuseppe , Bentall, Andrew , Loupy, Alexandre

Mayo Clinic

BMJ | May 31, 2023 | Volume: 381 | Issue: No issue available | Pages: e073654

10.1136/bmj-2022-073654 | PMID 37257905 Get It

Abstract Objective To compare the performance of a newly developed race-free kidney recipient specific glomerular filtration rate (GFR) equation with the three current main equations for measuring GFR in kidney transplant recipients. Design Development and validation study Setting 17 cohorts in Europe, the United States, and Australia (14 transplant centres, three clinical trials). Participants 15 489 adults (3622 in development cohort (Necker, Saint Louis, and Toulouse hospitals, France), 11 867 in multiple external validation cohorts) who received kidney transplants between 1 January 2000 and 1 January 2021. Main outcome measure The main outcome measure was GFR, measured according to local practice. Performance of the GFR equations was assessed using P 30 (proportion of estimated GFR (eGFR) within 30% of measured GFR (mGFR)) and correct classification (agreement between eGFR and mGFR according to GFR stages). The race-free equation, based on creatinine level, age, and sex, was developed using additive and multiplicative linear regressions, and its performance was compared with the three current main GFR equations: Modification of Diet in Renal Disease (MDRD) equation, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 equation, and race-free CKD-EPI 2021 equation. Results The study included 15 489 participants, with 50 464 mGFR and eGFR values. The mean GFR was 53.18 mL/min/1.73m 2 (SD 17.23) in the development cohort and 55.90 mL/min/1.73m 2 (19.69) in the external validation cohorts. Among the current GFR equations, the race-free CKD-EPI 2021 equation showed the lowest performance compared with the MDRD and CKD-EPI 2009 equations. When race was included in the kidney recipient specific GFR equation, performance did not increase. The race-free kidney recipient specific GFR equation showed significantly improved performance compared with the race-free CKD-EPI 2021 equation and performed well in the external validation cohorts (P 30 ranging from 73.0% to 91.3%). The race-free kidney recipient specific GFR equation performed well in several subpopulations of kidney transplant recipients stratified by race (P 30 73.0-91.3%), sex (72.7-91.4%), age (70.3-92.0%), body mass index (64.5-100%), donor type (58.5-92.9%), donor age (68.3-94.3%), treatment (78.5-85.2%), creatinine level (72.8-91.3%), GFR measurement method (73.0-91.3%), and timing of GFR measurement post-transplant (72.9-95.5%). An online application was developed that estimates GFR based on recipient’s creatinine level, age, and sex ( https://transplant-prediction-system.shinyapps.io/eGFR_equation_KTX/ ). Conclusion A new race-free kidney recipient specific GFR equation was developed and validated using multiple, large, international cohorts of kidney transplant recipients. The equation showed high accuracy and outperformed the race-free CKD-EPI 2021 equation that was developed in individuals with native kidneys. Trial registration ClinicalTrials.gov NCT05229939 .
Molecular classification and identification of an aggressive signature in low‐grade B‐cell lymphomas
Hopper, Melissa A. , Wenzl, Kerstin , Hartert, Keenan T. , Krull, Jordan E. , Dropik, Abigail R. , Serres, MaKayla R., Sarangi, Vivekananda , Yang, Zhi‐Zhang, Link, Brian K. , Ansell, Stephen M. , Novak, Anne J. , Paludo, Jonas , McPhail, Ellen Darcy , Link, Brian K , Krull, Jordan E , Hopper, Melissa A , Dropik, Abigail R , Novak, Joseph P. , Manske, Michelle K. , Larson, Melissa C. , Maurer, Matthew J. , Paludo, Jonas , Habermann, Thomas M. , Rimsza, Lisa M. , Cerhan, James R. , Jevremović, Dragan

Mayo Clinic

Hematological Oncology | May 31, 2023 | Volume: 41 | Issue: 4 | Pages: 644-654

10.1002/hon.3187 | PMID 37254453 Get It

Abstract Non‐follicular low‐grade B‐cell lymphomas (LGBCL) are biologically diverse entities that share clinical and histologic features that make definitive pathologic categorization challenging. While most patients with LGBCL have an indolent course, some experience aggressive disease, highlighting additional heterogeneity across these subtypes. To investigate the potential for shared biology across subtypes, we performed RNA sequencing and applied machine learning approaches that identified five clusters of patients that grouped independently of subtype. One cluster was characterized by inferior outcome, upregulation of cell cycle genes, and increased tumor immune cell content. Integration of whole exome sequencing identified novel LGBCL mutations and enrichment of TNFAIP3 and BCL2 alterations in the poor survival cluster. Building on this, we further refined a transcriptomic signature associated with early clinical failure in two independent cohorts. Taken together, this study identifies unique clusters of LGBCL defined by novel gene expression signatures and immune profiles associated with outcome across diagnostic subtypes.
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease
Haley, Connie A. , Ashkin, David , Peloquin, Charles A. , Cegielski, J. Peter , Andrino, Barbara B, Burgos, Marcos, Caloia, Lori A, Chen, Lisa , Colón‐Semidey, Angel, DeSilva, Malini B. , Dhanireddy, Shireesha , Dorman, Susan E. , Dworkin, Felicia , Hammond-Epstein, Heidi, Easton, Alice V. , Gaensbauer, James , Ghassemieh, Bijan J., Gómez, María Elena, Horné, David , Jasuja, Supriya , Jones, Betsy A., Kaplan, Leonard J., Khan, Asharaf Edward, Kracen, Elizabeth, Labuda, Sarah M. , Landers, Karen M., Lardizabal, Alfred , Lasley, Maria T, Letzer, David, Lopes, Vinicius K, Lubelchek, Ronald , Macias, C. Patricia, Mihalyov, Aimee, Misch, Elizabeth Ann , Murray, Jason A., Nilsen, Diana , Ninneman, M.J., Ogawa, Lynne, Oladele, Alawode, Overman, Melissa C, Ritger, Kathleen A., Rowlinson, Marie‐Claire , Sabuwala, Nadya, Schiller, Thomas M, Schwartz, Lawrence E., Spitters, Christopher, Thomson, Douglas B, Tresgallo, Rene Rico, Valois, Patrick , Goswami, Neela D. , Group, for the BPaL Implementation, Agraz-Lara, Rocio, Ahmed, Amina , Alvarez, Ana , Armitage, Lisa, Belknap, Robert , Bravo, Mary, Brode, Sarah K. , Burden, Elizabeth, Burzynski, Joseph , Caplan‐Shaw, Caralee , Castro, Ken, Chorba, Terry, Cook, Victoria , Cruz, Andrea T. , Dasgupta, Shom, Dhingra, Sonia, Elmore, Ellen, Erwin, Frank, Escuyer, Vincent, Fiske, Christina T. , Gadkowski, Beth, Henestroza, Germán, Higashi, Julie, Keh, Chris , Khalil, Amanda , Kigonya, Lilian, Lauzardo, Michael , Morris, Sapna Bamrah , Nabity, Scott A. , Oxtoby, Margaret J., Patrawalla, Amee , Raftery, Ann, Reed, Caitlin , Rock, Brian, Russo, Kelly, Sahini, Harleen, Saleeb, Paul , Santos, Roberto P. , Seaworth, Barbara , Shaw-Kaikai, Joanna, Starke, J R, Stout, Jason E. , Stubblefield, Wesley, Temesgen, Zelalem , Thomas, Keziah, Urbine, Daniel , Warkentin, Jon, Webb, Risa M. , Wortham, Johnathan, Yu, and Salinia, Altman, C, Hafiz, Irfan, Prabhakar, Deepa, Bowler, William, Gaensbauer, James T , Peloquin, Charles A , Schechter, Marcos C , Narita, Masahiro , Ray, Susan M , Group, for the BPaL Implementation, Alvarez, Ana, Armitage, Lisa, Barry, Pennan M. , Bernardo, John , Connors, William J. A. , Daley, Charles L. , Dobbs, Thomas E. , Escuyer, Vincent , Katrak, Shereen S. , Munsiff, Sonal S. , Phillips, Allison, Stubblefield, Wes, Thomas, Keziah, Tornheim, Jeffrey A. , Upton, Caryn M. , Wang, Shuhua , Wilson, John , Altman, Claudia

Mayo Clinic

Clinical Infectious Diseases | May 30, 2023 | Volume: 77 | Issue: 7 | Pages: 1053-1062

10.1093/cid/ciad312 | PMID 37249079 Get It

Abstract Background Rifampin-resistant tuberculosis is a leading cause of morbidity worldwide; only one-third of persons start treatment, and outcomes are often inadequate. Several trials demonstrate 90% efficacy using an all-oral, 6-month regimen of bedaquiline, pretomanid, and linezolid (BPaL), but significant toxicity occurred using 1200-mg linezolid. After US Food and Drug Administration approval in 2019, some US clinicians rapidly implemented BPaL using an initial 600-mg linezolid dose adjusted by serum drug concentrations and clinical monitoring. Methods Data from US patients treated with BPaL between 14 October 2019 and 30 April 2022 were compiled and analyzed by the BPaL Implementation Group (BIG), including baseline examination and laboratory, electrocardiographic, and clinical monitoring throughout treatment and follow-up. Linezolid dosing and clinical management was provider driven, and most patients had linezolid adjusted by therapeutic drug monitoring. Results Of 70 patients starting BPaL, 2 changed to rifampin-based therapy, 68 (97.1%) completed BPaL, and 2 of the 68 (2.9%) experienced relapse after completion. Using an initial 600-mg linezolid dose daily adjusted by therapeutic drug monitoring and careful clinical and laboratory monitoring for adverse effects, supportive care, and expert consultation throughout BPaL treatment, 3 patients (4.4%) with hematologic toxicity and 4 (5.9%) with neurotoxicity required a change in linezolid dose or frequency. The median BPaL duration was 6 months. Conclusions BPaL has transformed treatment for rifampin-resistant or intolerant tuberculosis. In this cohort, effective treatment required less than half the duration recommended in 2019 US guidelines for drug-resistant tuberculosis. Use of individualized linezolid dosing and monitoring likely enhanced safety and treatment completion. The BIG cohort demonstrates that early implementation of new tuberculosis treatments in the United States is feasible.
Airway luminal area in long COVID patients compared to acute COVID-19 patients
Zaremba, Solomiia , Miller, Alex , Ovrom, Erik A. , Dominelli, Paolo B. , Joyner, Michael J. , Welch, Brian T. , Miller, Alex J. , Joyner, Michael J , Senefeld, Jonathon W. , Wiggins, Chad C. , Ramsook, Andrew H

Mayo Clinic

Physiology | May 29, 2023 | Volume: 38 | Issue: S1 | Pages: No page available

10.1152/physiol.2023.38.s1.5731335 Get It

Background: Patients with respiratory manifestations of acute COVID-19 infection have enlarged luminal areas of central conducting airways demonstrated on computed tomography imaging and abnormal pulmonary function. In some cases, COVID-19 symptoms may persist for more than 4 weeks, referred to as long COVID, and the effect on airway luminal area remains unknown. Herein, we report airway luminal cross-sections areas among a long COVID group, compared to individuals with an acute COVID-19. We aim to investigate if large conducting airways sizes are different between acute COVID-19 and long COVID patients. Methods: A cohort of 181 people with long COVID were screened, of which 20 people (9 men, 11 women; 55.9 ± 14.1 years) were included in analyses. Twenty age, height, and sex matched patients with an acute (< 4 weeks of persistent symptoms from diagnosis) COVID-19 infection (55.7 ± 15.2 years) served as a comparison group. We used a three-dimensional reconstruction of computed tomography imaging to measure luminal areas of the trachea, right and left main bronchi, bronchus intermediate, right and left upper lobe, and left lower lobe bronchi at proximal, middle, and distal cross-sectional points in both groups. Airway luminal area was taken as the average of the three points. We compared average lumen area of long COVID patients with acute COVID-19 individuals, using an independent samples t-test. Results: We found no significant difference comparing measurements of the following airway luminal cross-sectional areas: trachea (277.7 ± 100.4 vs. 268.0 ± 70.5 mm2 p=0.73), right main bronchus (191.0 ± 66.1 vs. 190.1 ± 49.0 mm2, p=0.96), bronchus intermediate (112.3 ± 33.4 vs. 109.3 ± 27.9 mm2, p=0.76), right upper lobe bronchus (74.4 ± 21.0 vs. 73.7 ± 25.5 mm2, p=0.92), left main bronchus (129.1 ± 50.1 vs. 136.9 ± 38.0 mm2, p=0.58), left lower lobe bronchus (57.8 ± 18.2 vs. 59.0 ± 13.4 mm2, p=0.82), and left upper lobe bronchus (80.1 ± 19.5 vs. 77.9 ± 22.9 mm2, p=0.75) in the long COVID and acute COVID-19 groups respectively. Conclusion: In patients with long COVID, compared to those with an acute COVID-19 infection, we did not see differences in central airway luminal areas. Further analysis of a larger cohort is needed to determine whether enlarged airway luminal areas, associated with acute COVID-19, persist in long COVID. This research will expand knowledge on functional consequences for patients with long COVID. Funding: F32HL154320 to JWS; 5R35HL139854 to MJJ. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
Sex differences in central airway luminal area among people with interstitial lung disease
Miller, Alex, Ovrom, Erik A. , Dominelli, Paolo B. , Joyner, Michael J. , Welch, Brian T. , Miller, Alex J. , Joyner, Michael J , Miller, Alex, Senefeld, Jonathon W. , Wiggins, Chad C. , Ramsook, Andrew H

Mayo Clinic

Physiology | May 29, 2023 | Volume: 38 | Issue: S1 | Pages: No page available

10.1152/physiol.2023.38.s1.5731276 Get It

Background: Interstitial lung disease (ILD) encompasses several pulmonary disorders associated with scarring and fibrosis of pulmonary tissue. People with idiopathic pulmonary fibrosis, a subset of ILD, have greater central airway luminal area compared to age- and sex-matched healthy controls when evaluated using microcomputed tomography, a process examining the luminal area of ex-vivo lung tissue. In this study we aimed to confirm these findings using a different method of airway assessment, three-dimensional (3D) reconstruction of computed tomography (CT) scans. Moreover, in health, males have larger central airways than height-matched females, but it remains unknown if there are sex differences in airway area among people with ILD. We hypothesized that sex differences observed in healthy people would persist among people with ILD. Methods: A cohort of 399 patients with lung CT scans were screened, of which 19 people (7 females) with ILD were included in analyses after exclusions. People with ILD were matched based on sex, age, and height to 19 healthy controls. We assessed cross-sectional luminal area at the midpoint of seven conducting airways (trachea, left and right main bronchus, intermediate bronchus, left and right upper lobe, and left lower lobe). Results from pulmonary function tests were also abstracted, as available. To examine sex differences, we compared airway luminal area, normalized to participant height, between males and females with ILD. Sex differences were analyzed using a univariate ANOVA test. Results: People with ILD had a preserved ratio of forced expiratory volume in the first second to forced vital capacity (101 ±12%predicted) and decreased diffusing capacity for carbon monoxide (55 ±23%predicted). People with ILD had airways that were between 19.6%-45.0% larger than controls (p<0.05). Composite physiologic index, a marker of ILD severity, was not different between sexes (p=0.07). Males with ILD had significantly larger, luminal areas than females in two central airways - right main bronchus (1.46±0.41 vs. 1.07±0.22 mm2/cm, p=0.04) and left upper lobe (0.54±0.10 vs. 0.43±0.08 mm2/cm, p=0.02). However, luminal area of other central airways, including: trachea (2.15±0.57 vs. 1.65±0.32 mm2/cm, p=0.051), bronchus intermediate (0.77±0.23 vs. 0.61±0.13 mm2/cm, p=0.12), right upper lobe (0.47±0.15 vs. 0.40±0.06 mm2/cm, p=0.26), left main bronchus (0.93±0.33 vs. 0.69±0.16 mm2/cm, p=0.09), and left lower lobe (0.41±0.13 vs. 0.40±0.08 mm2 /cm, p=0.79) were not different between sexes in people with ILD. Conclusion: Sex differences observed in healthy people are potentially preserved in ILD, but a more robust sample is required to fully elucidate these findings. Illuminating any sex differences in ILD pathophysiology may provide knowledge to treat and improve clinical outcomes in ILD. Funding: National Heart, Lung, and Blood Institute (F32HL154320 to JWS; 5R35HL139854 to MJJ). This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
Inclusion, Diversity, Access, and Equity in Infectious Diseases Fellowship Training: Tools for Program Directors
Luther, Vera , Barsoumian, Alice E , Konold, Victoria , Balba, Gayle , Benson, Constance A. , Blackburn, Brian G. , Cariello, Paloma F, Perloff, Sarah , Acharya, Kartikey, Bhanot, Nitin , Blyth, Dana M , Casańas, Beata, Chow, Brian , Cutrell, James B , Doshi, Saumil, Finkel, Diana , Graber, Christopher J. , Hazra, Aniruddha , James, Scott H. , Kodiyanplakkal, Rosy Priya , Lee, Mi-Kyung , Marcos, Luis A. , Lora, Alfredo J Mena , Moore, Christopher C. , Nnedu, Obinna, Osorio, Georgina, Reece, Rebecca , Salas, Natalie Mariam , Sanasi-Bhola, Kamla, Schultz, Sara , Serpa, José A., Shnekendorf, Rachel, Wooten, Darcy , Zuckerman, Richard A. , Melia, Michael T. , Chirch, Lisa M , Luther, Vera P , Razonable, Raymund, Azar, Marwan M , Graber, Christopher J , Lee, Mikyung , Vijayan, Tara , Razonable, Raymund R. , Azar, Marwan M. , Butt, Saira , Cleveland, Kerry O. , Hochberg, Natasha S. , Kaltsas, Anna , Paras, Molly L , Weisenberg, Scott A.

Mayo Clinic

Open Forum Infectious Diseases | May 27, 2023 | Volume: 10 | Issue: 6 | Pages: No page available

10.1093/ofid/ofad289 | PMID 37397270 Get It

Abstract The Infectious Diseases Society of America (IDSA) has set clear priorities in recent years to promote inclusion, diversity, access, and equity (IDA&E) in infectious disease (ID) clinical practice, medical education, and research. The IDSA IDA&E Task Force was launched in 2018 to ensure implementation of these principles. The IDSA Training Program Directors Committee met in 2021 and discussed IDA&E best practices as they pertain to the education of ID fellows. Committee members sought to develop specific goals and strategies related to recruitment, clinical training, didactics, and faculty development. This article represents a presentation of ideas brought forth at the meeting in those spheres and is meant to serve as a reference document for ID training program directors seeking guidance in this area.
Paired Indoor and Outdoor Nitrogen Dioxide Associated With Childhood Asthma Outcomes in a Mixed Rural-Urban Setting: A Feasibility Study
Wi, Chung‐Il , Gent, Janneane F., Bublitz, Joshua T., Ryu, Euijung , Sorrentino, Keli, Plano, Julie, McKay, Lisa A. , Porcher, Julie C., Wheeler, Philip H., DeWan, Andrew T. , Sheares, Beverley J. , Leaderer, Brian P., Juhn, Young J. , King, Katherine S. , Porcher, Julie, Chiarella, Sergio E , DeWan, Andrew T , Wi, Chung-Ii , Chiarella, Sergio E. , Pollitt, Krystal J. Godri

Mayo Clinic

Journal of Primary Care & Community Health | May 27, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/21501319231173813 | PMID 37243352 Get It

Introduction: Nitrogen dioxide (NO 2 ) is known to be a trigger for asthma exacerbation. However, little is known about the role of seasonal variation in indoor and outdoor NO 2 levels in childhood asthma in a mixed rural-urban setting of North America. Methods: This prospective cohort study, as a feasibility study, included 62 families with children (5-17 years) that had diagnosed persistent asthma residing in Olmsted County, Minnesota. Indoor and outdoor NO 2 concentrations were measured using passive air samples over 2 weeks in winter and 2 weeks in summer. We assessed seasonal variation in NO 2 levels in urban and rural residential areas and the association with asthma control status collected from participants’ asthma diaries during the study period. Results: Outdoor NO 2 levels were lower (median: 2.4 parts per billion (ppb) in summer, 3.9 ppb in winter) than the Environmental Protection Agency (EPA) annual standard (53 ppb). In winter, a higher level of outdoor NO 2 was significantly associated with urban residential living area ( P = .014) and lower socioeconomic status (SES) ( P = .027). For both seasons, indoor NO 2 was significantly higher ( P < .05) in rural versus urban areas and in homes with gas versus electric stoves ( P < .05). Asthma control status was not associated with level of indoor or outdoor NO 2 in this cohort. Conclusions: NO 2 levels were low in this mixed rural-urban community and not associated with asthma control status in this small feasibility study. Further research with a larger sample size is warranted for defining a lower threshold of NO 2 concentration with health effect on asthma in mixed rural-urban settings.
The clot thickens: How to use viscoelastic testing in critical illness
Rech, Megan A. , Nei, Scott D. , Brown, Caitlin S. , Rech, Megan A , Gilbert, Brian W. , Garg, Ravi

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | May 27, 2023 | Volume: 6 | Issue: 8 | Pages: 954-963

10.1002/jac5.1829 Get It

AbstractCoagulopathy is common in critically ill patients and may result in complications such as bleeding or thromboembolic events. Viscoelastic testing (VET), including both thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®), offers a benefit over conventional coagulation tests in that it provides a qualitative and quantitative assessment of the degree of coagulopathy, including the ability to measure fibrinolysis. This review is a “how‐to” primer for critical care pharmacists to interpret and utilize VET in practice across a spectrum of coagulopathies, including trauma and traumatic brain injury, neurologic injury and emergencies, cardiothoracic surgery, liver disease, and medication‐induced coagulopathy.
Assessment of the Inter-observer Variability of the Radiomic Tools: BRODERS (Benign vs aggressive nODule Evaluation using Radiomic Stratification) and SILA (Score Indicative of Lung cancer Aggression) to Classify Lung Nodules
Al-Ghoula, Faysal, FALDE, SAMUEL D, Rajagopalan, Srinivasan, Maldonado, Fabien , Peikert, Tobias, Bartholmai, Brian J. , Bartholmai, Brian J , Patel, Khushbu

Mayo Clinic

No container title available | May 24, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2884203/v1 Get It

Abstract Introduction: While CT lung cancer screening reduces lung cancer-specific mortality, there are remaining challenges. Radiomic tools promiss to address these challenges, however, they are subject to interobserver variability if semi-automated segmentation techniques are used. Herein we report interobserver variability for two validated radiomic tools, BRODERS (Benign versus aggRessive nODule Evaluation using Radiomic Stratification) and CANARY (Computer-Aided Nodule Assessment and Risk Yield). Methods We retrospectively analyzed the CT images of 95 malignant lung nodules of the adenocarcinoma spectrum using BRODERS and CANARY. Cases were identified at Mayo Clinic (n = 45) and Vanderbilt University Medical Center and Nashville/Veteran Administration Tennessee Valley Health Care System (n = 50). Three observers with different training levels (medical student, internal medicine resident and thoracic radiology fellow) each performed lung nodule segmentation. All methods were carried out in accordance with relevant guidelines and regulations Results Interclass correlation coefficients (ICC) of 0.77, 0.98 and 0.97 for the average nodule volume, BRODERS cancer probability and Score Indicative of Lesion Aggression (SILA) which summarizes the distribution of the CANARY exemplars indicated good to excellent reliability, respectively. The dice similarity coefficient was 0.79 and 0.81 for the data sets from the two institutions. Conclusion: BRODERS and CANARY are robust radiomics tools with excellent interobserver variability. These tools are simple and reliable regardless the observer/operator’s level of training.
Cybersecurity and Technical Patient Privacy Protection
Nachbar, James M., Kinney, Brian M. , Sacks, Justin M. , Gurtner, Geoff C., TerKonda, Sarvam P. , Reddy, Sashank , Jeffers, Lynn L., Jeffers, Lynn

Mayo Clinic

Plastic & Reconstructive Surgery | May 23, 2023 | Volume: 154 | Issue: 1 | Pages: 250-257

10.1097/prs.0000000000010740 | PMID 37220229 Get It

Summary: Plastic surgery offices are subject to a wide variety of cybersecurity threats, including ransomware attacks that encrypt the plastic surgeon’s information and make it unusable, as well as data theft and disclosure attacks that threaten to disclose confidential patient information. Cloud-based office systems increase the attack surface and do not mitigate the effects of breaches that can result in theft of credentials. Although employee education is often recommended to avoid the threats, a single error by a single employee has often led to security breaches, and it is unreasonable to expect that no employee will ever make an error. Recognition of the 2 most common vectors of these breaches—compromised email attachments and surfing to compromised websites—allows the use of technical networking tools to prevent both email attachments from being received and employee use of unsanctioned and potentially compromised websites. Furthermore, once compromised code has been allowed to run within the office network, that code must necessarily make outbound connections to exploit the breach. Preventing that outbound traffic can mitigate the effects of a breach. However, most small office network consultants design firewalls to only limit incoming network traffic and fail to implement technical measures to stop the unauthorized outbound traffic that is necessary for most network attacks. The authors provide detailed techniques that can be used to direct information technology consultants to properly limit outbound network traffic as well as incoming email attachments.